The group has broad interests, and its main research lines are:
(a) Anticancer compounds, either based on the optimization of natural models or designed to bind specific cancer targets, including topoisomerases and the TRPM8 calcium channel, an emerging target in prostate cancer.
(b) Multitarget compounds for other areas of chemotherapy, particularly tuberculosis and leishmaniasis.
(c) Multitarget-directed ligands for neurodegenerative diseases, including Alzheimer's disease and brain ischemia.
(d) Diversity-oriented synthesis for lead discovery, based on in-house developed domino and multicomponent reactions. Green synthesis.